|
PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Notes that deupirfenidone, also known as LYT-100, slows lung function decline in people with idiopathic pulmonary fibrosis as measured by forced vital capacity in a phase 2b trial. Toby Maher, professor of medicine & director of interstitial lung disease at Keck School of Medicine at the University of Southern California in Los Angeles, and lead investigator in the Elevate IPF trial, says: ‘Deupirfenidone has the potential to offer patients a highly effective and tolerable treatment option. These are extremely exciting results from a phase 2b trial, and I am very enthusiastic about the continued development of deupirfenidone.’ Current stock price: 173.60 pence each, up 6.6% on Monday afternoon in London 12-month change: up 15% Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
